The success of BioChem Pharma Inc.'s lamivudine in a Phase III trial in chronic hepatitis B hasn't discouraged other companies developing therapies for the disease. Rather, they assume that treatment of HBV, as with AIDS, will be based on combination therapies.

Last week, BCHXF's partner, Glaxo Wellcome, presented positive results from the first of nine Phase III trials (see BioCentury Extra April 11). Based on the results, Glaxo (London, U.K.) plans to begin filing for regulatory approvals starting in Asian countries later this year.